Clinical Trials Logo

Clinical Trial Summary

To estimate the incidence of febrile neutropenia in patients with breast cancer and non-Hodgkin's lymphoma receiving high (> 20%) FN-risk chemotherapy and pegfilgrastim primary prophylaxis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02178475
Study type Observational
Source Amgen
Contact
Status Completed
Phase
Start date July 18, 2014
Completion date October 28, 2016

See also
  Status Clinical Trial Phase
Completed NCT02467868 - Efficacy and Safety Study With MYL-1401H and Neulasta Phase 3
Completed NCT04000711 - Safety and Efficacy of Ambulatory Versus In-hospital Antibiotic Treatment in Children With Febrile Neutropenia N/A
Recruiting NCT03823950 - Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients Phase 4
Completed NCT01813721 - Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy. N/A